



Press Release

VanEck launches bionic engineering ETF

- **Bionics provide solutions for the diseases and disabilities of the ageing population**
- **The VanEck Bionic Engineering UCITS ETF invests in companies that create solutions for medical implants or artificial body parts**
- **With the new ETF, VanEck is expanding its range of impact products**

London, 07 December 2022 – Asset manager VanEck is listing the *VanEck Bionic Engineering UCITS ETF* today on both the London Stock Exchange and the German stock exchange Xetra. The new ETF allows investors to invest in companies from the bionics sector.

Bionics involves research and development of approaches for developing technical applications based on the model of living systems. The fundamental notion of bionics is the transfer of biology to technology. In the context of healthcare, the term “bionics” represents technologies designed to enhance or restore functions of human body. Fine examples of bionic engineering include prosthetics, bio-printed tissues, replacement organs and body function aids.

“The proportion of the elderly population is rising and with it the demand for technical solutions such as hearing and visual aids, pacemakers, artificial joints and the like that improve the quality of life in the old age,” says Martijn Rozemuller, CEO at VanEck Europe. “At the same time, increasingly available bionic tools are helping people with chronic diseases such as diabetes or functional disorders.”

“As the technology develops, we expect the applications based on functions of the brain and nerve systems to become more prominent. Bionics also have the potential to disrupt healthcare, with innovations like neuroprosthetics enabling treatment of Alzheimer’s and other cognitive diseases as well as direct brain-to-device communication for paralyzed people.” adds Dominik Schmaus, Product Manager at VanEck Europe. “Bionic Engineering can also be a factor for change in social attitudes. It can reduce stigma and discrimination that people with disability often experience.”

Pure-play investments in companies that manufacture medical implants

The VanEck Bionic Engineering UCITS ETF follows the MVIS® Global Bionic Healthcare ESG Index, which tracks the performance of companies involved in medical, dental or visual implants, bioprinting, prosthetics or organ and tissue preservation. The accumulating VanEck Bionic Engineering UCITS ETF has a total expense ratio (TER) of 0.55 per cent and is rebalanced quarterly.

The ETF excludes companies that manufacture implantable or wearable devices or materials used only for cosmetic purposes. The index also excludes companies that have committed very serious violations of social norms, generate sales from controversial weapons or exceed certain thresholds for their sales in various sectors, such as civilian firearms or tobacco.



Equity market risk: The prices of securities in the fund are subject to the risks inherent in investing in the securities market, including general economic conditions and sudden and unpredictable price drops. An investment in the fund may result in losses.

ETF	VanEck Bionic Engineering UCITS ETF
ISIN Code	IE0005TF96I9
Ticker LSE USD / GBP	CYBO / CYBG
Bloomberg	CYBO LN / CYBG LN
Ticker Xetra	CIB0
SFDR classification	Article 9
Investment manager	VanEck Asset Management B.V.
Fund domicile	Ireland
Index provider	MarketVector Indexes GmbH
Base currency	US Dollar
Rebalancing	Quarterly
Product structure	Physical (Full replication)
Income treatment	Accumulating
Listing Date	7 December 2022
Total expense ratio (TER)	0.55% p.a.

Contact:

Henning Mönster / Miriam Wolschon
public imaging GmbH
Tel.: +49 (0)40 401999-156 / -155
E-mail: vaneck@publicimaging.de

Guy Taylor
Peregrine Communications
Tel.: +44 (0) 20 3040 0867
E-Mail: vaneck@peregrinecommunications.com

About VanEck

VanEck has a history of looking beyond the financial markets to identify trends that are likely to create impactful investment opportunities. As of November 30, 2022, VanEck managed approximately 72 US Dollar billion in assets, including mutual funds, ETFs and institutional accounts.



With more than 90 ETFs globally, the asset manager offers a comprehensive portfolio covering numerous sectors, asset classes and smart beta strategies. VanEck was one of the first asset managers to offer investors access to international markets. The objective has always been to identify new trends and asset classes – such as Gold Investments (1968), Emerging Markets (1993) and ETFs (2006), which have shaped the investment industry to this day.

VanEck is headquartered in New York City and has offices in Frankfurt (Germany), Pfaeffikon (Switzerland), Amsterdam (Netherlands), Sydney (Australia) and Shanghai (China).

Important Disclosures

For informational and advertising purposes only.

This information originates from VanEck (Europe) GmbH which has been appointed as distributor of VanEck products in Europe by the Management Company VanEck Asset Management B.V., incorporated under Dutch law and registered with the Dutch Authority for the Financial Markets (AFM). VanEck (Europe) GmbH with registered address at Kreuznacher Str. 30, 60486 Frankfurt, Germany, is a financial services provider regulated by the Federal Financial Supervisory Authority in Germany (BaFin). The information is intended only to provide general and preliminary information to investors and shall not be construed as investment, legal or tax advice. VanEck (Europe) GmbH and its associated and affiliated companies (together “VanEck”) assume no liability with regards to any investment, divestment or retention decision taken by the investor on the basis of this information. The views and opinions expressed are those of the author(s) but not necessarily those of VanEck. Opinions are current as of the publication date and are subject to change with market conditions. Certain statements contained herein may constitute projections, forecasts and other forward looking statements, which do not reflect actual results. Information provided by third party sources are believed to be reliable and have not been independently verified for accuracy or completeness and cannot be guaranteed. All indices mentioned are measures of common market sectors and performance. It is not possible to invest directly in an index.

VanEck Asset Management B.V., the management company of VanEck Bionic Engineering UCITS ETF (the "ETF"), a sub-fund of VanEck UCITS ETFs plc, is a UCITS management company incorporated under Dutch law registered with the Dutch Authority for the Financial Markets (AFM). The ETF is registered with the Central Bank of Ireland and tracks an equity index. The value of the ETF's assets may fluctuate heavily as a result of the investment strategy. If the underlying index falls in value, the ETF will also lose value. Investors must read the sales prospectus and key investor information before investing in a fund. These are available in English and the KIIDs/KIDs in certain other languages as applicable and can be obtained free of charge at www.vaneck.com, from the local information agent Computershare Investor Services PLC or from the Management Company.

MVIS® Global Bionic Healthcare ESG Index is the exclusive property of MarketVector Indexes GmbH (a wholly owned subsidiary of Van Eck Associates Corporation), which has contracted with Solactive AG to maintain and calculate the Index. Solactive AG uses its best efforts to ensure that the Index is calculated correctly. Irrespective of its obligations towards MarketVector Indexes GmbH (“MarketVector”), Solactive AG has no obligation to point out errors in the Index to third parties. The VanEck Bionic Engineering UCITS ETF is not sponsored, endorsed, sold or promoted by MarketVector and MarketVector makes no representation regarding the advisability of investing in the Fund.

All performance information is historical and is no guarantee of future results. Investing is subject to risk, including the possible loss of principal. You must read the Prospectus and KIID before investing in a fund.

No part of this material may be reproduced in any form, or referred to in any other publication, without express written permission of VanEck.

© VanEck (Europe) GmbH